Natia Murvelashvili
Endocrinology, Diabetes & Metabolism · Spartanburg, SCNPI 1225551781
Payments from drug & device makers
Across 77 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$251
- Lilly USA, LLC$177
- Sanofi-aventis U.S. LLC$166
- BETA Bionics, Inc.$145
- Novo Nordisk$120
- Boehringer Ingelheim$100
- plus $671 from 16 others
What the payments were for
- Food & beverage$1,629100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $251 |
| Lilly USA, LLC | 10 | $177 |
| Sanofi-aventis U.S. LLC | 6 | $166 |
| BETA Bionics, Inc. | 1 | $145 |
| Novo Nordisk | 8 | $120 |
| Boehringer Ingelheim | 6 | $100 |
| Sequel Med Tech, LLC | 5 | $100 |
| Radius Health, Inc. | 4 | $91 |
| Insulet Corporation | 3 | $75 |
| Tandem Diabetes Care, Inc. | 3 | $69 |
| Ascendis Pharma Endocrinology Inc | 3 | $55 |
| Cequr Corporation | 3 | $51 |
| Dexcom, Inc. | 2 | $43 |
| Nevro Corp. | 1 | $30 |
| Merck | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| AstraZeneca | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Novartis | 1 | $18 |
| Medtronic | 1 | $15 |
| Globus Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,629 in reported general payments places this provider in the 35th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 293 | $439,908 |
| MounjaroTirzepatide | 149 | $200,198 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 69 | $137,402 |
| JardianceEmpagliflozin | 92 | $114,474 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $110,434 |
| TrulicityDulaglutide | 77 | $108,948 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $93,959 |
| Tresiba Flextouch U-200Insulin Degludec | 78 | $91,642 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $83,993 |
| FarxigaDapagliflozin Propanediol | 80 | $82,374 |
| Novolog FlexpenInsulin Aspart | 187 | $74,382 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $39,508 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $34,648 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $29,400 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $27,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $120 | $584,329383 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30, Humalog | $177 | $314,507253 claims |
| Boehringer IngelheimJardiance | $100 | $114,47492 claims |
| AstraZenecaFarxiga | $19 | $82,37480 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $166 | $32,32532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Spartanburg
- Ronald MayfieldSpartanburg$8.9M
- Mayte SandrinSpartanburg$10K
- Donald EagertonMyrtle Beach$7.9M
- Beatrice HullCharleston$987K
- Anne LarochelleMyrtle Beach$678K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Kathie HermayerCharleston$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.